Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 ...
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
Alkermes (ALKS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Alkermes (ALKS) Outpaced the Stock Market Today
Alkermes (ALKS) concluded the recent trading session at $29.45, signifying a +1.76% move from its prior day's close.
Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Alkermes (ALKS) stood at $29.69, denoting a -0.37% change from the preceding trading day.
Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript
Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.
Related Companies